Reduced Cancer Drug Reimbursements Don’t Impede Access – JAMA Study
This article was originally published in The Pink Sheet Daily
Executive Summary
2003-2006 Medicare claim review finds no evidence that lowering physician payments adversely affected access to care.
You may also be interested in...
Medicare Cancer Demo May Encourage Use Of EPO, Anti-Emetics
The Medicare program is earmarking $300 mil. for a "quality of care" demonstration project that should help smooth the transition to ASP-based reimbursement in 2005
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Rebate Proposals Targeting Single-Use Vials May Be Barking Up The Wrong Tree
Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: